Novel sulfonated and phosphonated analogs of distamycin which inhibit the replication of HIV.

A series of novel distamycin-related polyanionic compounds were compared for their anti-HIV activity. Several were highly potent inhibitors of HIV virus-induced cell killing and viral replication of a wide variety of laboratory isolates, as well as a monocytotropic virus and a clinical isolate in human peripheral blood lymphocytes. These compounds are structurally different from other sulfonic acid containing compounds reported to be potent inhibitors of the human immunodeficiency virus (HIV) in two respects: (1) they are structurally related to the non-toxic minor groove DNA binder distamycin; and (2) a number of them contain the aromatic phosphonic acid group. The compounds that were evaluated can be categorized into monomeric or dimeric ureido structural classes incorporating the bisamido-N-methylpyrrolenaphthalene-sulfonic acid group, with differences in the number and position of the sulfonic acids on the naphthalene rings. Broader structure-activity studies were made possible through the synthesis and evaluation of the compounds containing only a single N-methylpyrrole unit, those incorporating the N-methylpyrazole structure, and compounds having the isosteric phosphonic acid group substituted for the sulfonic acid group. One of the most potent of the inhibitors was 2,2'[4,4'[[aminocarbonyl]amino]bis[N,4'-di[pyrrole-2-carboxamide- 1,1'-dimethyl]]-4,6,8 naphthalenetrisulfonic acid] hexasodium salt, NSC 651015. This compound, the phosphonic acid analog NSC 662162, and the monomeric compound NSC 651018 were studied to determine the mechanism of their inhibitory activity. Mechanistic studies revealed that inhibition was due to the disruption of virus attachment to CD(4+)-susceptible cells and a further restraint on fusion of virus and cell membranes. The relative tolerance of these compounds in mice suggests that sufficient antiviral concentrations could be reached in vivo and thus may prove valuable in the treatment of AIDS patients.

[1]  O. Weislow,et al.  Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction. , 1994, Journal of medicinal chemistry.

[2]  M. Cloyd,et al.  Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates. , 1990, Virology.

[3]  W. Rice,et al.  The site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  F. Schabel,et al.  Inhibition of gross leukemia virus-induced plaque formation in XC cells by 3-deazauridine. , 1974, Journal of the National Cancer Institute.

[5]  O. Weislow,et al.  Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase , 1993, Antimicrobial Agents and Chemotherapy.

[6]  M. Boyd,et al.  New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. , 1989, Journal of the National Cancer Institute.

[7]  B. Haynes,et al.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.

[8]  S. Lagakos,et al.  The Concorde trial , 1993, The Lancet.

[9]  Philip R. Johnson,et al.  An African primate lentivirus (SIVsmclosely related to HIV-2 , 1989, Nature.

[10]  M. Prichard,et al.  A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.

[11]  M. Boyd,et al.  A semiautomated multiparameter approach for anti-HIV drug screening. , 1991, Journal of virological methods.

[12]  Paul Kellam,et al.  Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro , 1993, Nature.

[13]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[14]  J. Levy,et al.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. , 1984, Science.

[15]  Jerome A. Zack,et al.  HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.

[16]  E. Gruszecka-Kowalik,et al.  Quinobene, a new potent anti-HIV agent. , 1992, Biochemical and biophysical research communications.

[17]  E A Emini,et al.  Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors , 1991, Journal of virology.

[18]  G. Pavlakis,et al.  A bioassay for HIV-1 based on Env-CD4 interaction. , 1990, AIDS research and human retroviruses.

[19]  Michael S. Saag,et al.  A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1993 .

[20]  H. Mitsuya,et al.  Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. , 1991, Blood.

[21]  P. Nara,et al.  Quantitative infectivity assay for HIV-1 and -2 , 1988, Nature.

[22]  J. Louis,et al.  Purification of HIV‐1 wild‐type protease and characterization of proteolytically inactive HIV‐1 protease mutants by pepstatin A affinity chromatography , 1991, FEBS letters.

[23]  J. Levy,et al.  Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. , 1985, Virology.

[24]  M. Kozlowski,et al.  Inhibition of gp120 Binding to the CD4 Antigen by Dyes: Mechanism of Effect and Contribution to anti-HIV Activity , 1992 .

[25]  O. Weislow,et al.  Sulfonic Acid Dyes: Inhibition of the Human Immunodeficiency Virus and Mechanism of Action , 1992, Journal of acquired immune deficiency syndromes.

[26]  A. Fauci,et al.  Differential effect of monoclonal anti-DR antibody on monocytes in antigen- and mitogen-stimulated responses: mechanism of inhibition and relationship to interleukin 1 secretion. , 1983, Cellular immunology.

[27]  R. Swanstrom,et al.  Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. , 1991, AIDS research and human retroviruses.

[28]  B. Larder,et al.  Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture , 1994, Antimicrobial Agents and Chemotherapy.

[29]  M. Emerman,et al.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene , 1992, Journal of virology.

[30]  B. Larder,et al.  Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. , 1994, The Journal of general virology.